Clinical update on linezolid in the treatment of gram-positive bacterial infections

Infection and Drug Resistance

Volumn 5, Issue 1, 2012, Pages 87-102

  Ager, Sally ^a   Gould, Kate ^a  

^a FREEMAN HOSPITAL   (United Kingdom)

Author keywords

Cost benefit; Gram positive; Linezolid; MRSA; Multi resistant; Oxazolidinone; VRE

Indexed keywords

AMPICILLIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFPODOXIME; CEFTRIAXONE; CIPROFLOXACIN; CLARITHROMYCIN; CYTOCHROME P450; DALBAVANCIN; DAPTOMYCIN; GENTAMICIN; LINEZOLID; MOXIFLOXACIN; OXACILLIN; PENICILLIN G; POLYPEPTIDE ANTIBIOTIC AGENT; RIFAMPICIN; TEICOPLANIN; VANCOMYCIN;

ADIPOSE TISSUE; ANAEROBIC BACTERIUM; ANEMIA; ANGIONEUROTIC EDEMA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BACTEREMIA; BELL PALSY; BIOFILM; BONE INFECTION; BONE MARROW SUPPRESSION; BREAST MILK; CANDIDIASIS; CENTRAL NERVOUS SYSTEM INFECTION; CLOSTRIDIUM DIFFICILE INFECTION; COST EFFECTIVENESS ANALYSIS; DELAYED HYPERSENSITIVITY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRESS SYNDROME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; ENDOCARDITIS; FATTY LIVER; FEBRILE NEUTROPENIA; GRAM POSITIVE INFECTION; HEMATOLOGIC DISEASE; HOSPITAL INFECTION; HUMAN; INFECTIOUS ARTHRITIS; INSOMNIA; INTERSTITIAL NEPHRITIS; LACTIC ACIDOSIS; LIVER DYSFUNCTION; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIOSIS; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; NEPHRITIS; NONHUMAN; OPTIC NERVE DISEASE; OSTEOMYELITIS; PERIPHERAL NEUROPATHY; PNEUMONIA; PROPIONIBACTERIUM ACNES; PURE RED CELL ANEMIA; REVIEW; SEROTONIN SYNDROME; SINGLE DRUG DOSE; SKIN INFECTION; SKIN PENETRATION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS; TASTE DISORDER; THROMBOCYTOPENIA; TONGUE DISEASE; VOMITING;

EID: 84872959907     PISSN: 11786973     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (175)

1. Mouton JW, Jansz AR. The DUEL study:a multi-center in vitro evaluation of Linezolid compared with other antibiotics in The Netherlands. Clin Microbiol Infect. 2001;7(9):486-491.
2. Draghi DC, Sheehan DJ, Hogan P, Sahm DF. In vitro activity of linezolid against key gram-positive organisms isolated in the united states: results of the LEADER 2004 surveillance program. Antimicrob Agents Chemother. 2005;49(12):5024-5032.
3. Mutnick AH, Biedenbach DJ, Turnidge JD, Jones RN. Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000. Diagn Microbiol Infect Dis. 2002;43(1):65-73.
4. Jevitt LA, Smith AJ, Williams P P, Raney PM, McGowan JE Jr, Tenover FC. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium. Microb Drug Resist. 2003;9(4):389-393.
5. Fluegge K, Supper S, Siedler A, Berner R. Antibiotic susceptibility in neonatal invasive isolates of Streptococcus agalactiae in a 2-year nationwide surveillance study in Germany. Antimicrob Agents Chemother. 2004;48(11):4444-4446.
6. Jones RN, Stilwell MG, Hogan PA, Sheehan DJ. Activity of linezolid against 3,251 strains of uncommonly isolated gram-positive organisms: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother. 2007;51(4):1491-1493.
7. Betriu C, Redondo M, Palau ML, et al. Comparative in vitro activities of linezolid, quinupristin-dalfopristin, moxifoxacin, and trovafoxacin against erythromycin-susceptible and -resistant streptococci. Antimicrob Agents Chemother. 2000;44(7):1838-1841.
8. Kosowska-Shick K, Smith K, Bogdanovich T, Ednie LM, Jones RN, Appelbaum PC. Activity of DX-619 compared to other agents against viridans group streptococci, Streptococcus bovis, and Cardiobacterium hominis. Antimicrob Agents Chemother. 2006;50(12):4191-4194.
9. Zhanel GG, Palatnick L, Nichol KA, Bellyou T, Low DE, Hoban DJ. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother. 2003;47(6): 1867-1874.
10. Funke G, Nietznik C. Minimal inhibitory concentrations of linezolid against clinical isolates of coryneform bacteria. Eur J Clin Microbiol Infect Dis. 2005;24(9):612-614.
11. Klare I, Konstabel C, Werner G, et al. Antimicrobial susceptibilities of Lactobacillus, Pediococcus and Lactococcus human isolates and cultures intended for probiotic or nutritional use. J Antimicrob Chemother. 2007;59(5):900-912.
12. Bowersock TL, Salmon SA, Portis ES, et al. MICs of oxazolidinones for Rhodococcus equi strains isolated from humans and animals. Antimicrob Agents Chemother. 2000;44(5):1367-1369.
13. Brown-Elliott BA, Ward SC, Crist CJ, Mann LB, Wilson RW, Wallace RJ Jr. In vitro activities of linezolid against multiple Nocardia species. Antimicrob Agents Chemother. 2001;45(4):1295-1297.
14. Ackermann G, Adler D, Rodloff AC. In vitro activity of linezolid against Clostridium difficile. J Antimicrob Chemother. 2003;51(3):743-745.
15. Baines SD, Noel AR, Huscroft GS, et al. Evaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut model. J Antimicrob Chemother. 2011;66(7):1537-1546.
16. Daeschlein G, Hoehne C, Assadian O, et al. In vitro activity of linezolid against clinical isolates of Fusobacterium spp. J Antimicrob Chemother. 2006;58(4):789-793.
17. Citron DM, Merriam C V, Tyrrell KL, Warren YA, Fernandez H, Goldstein EJ. In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria. Antimicrob Agents Chemother. 2003; 47(7):2334-2338.
18. Molitoris D, Väisänen ML, Bolaños M, Finegold SM. In vitro activities of DX-619 and four comparator agents against 376 anaerobic bacterial isolates. Antimicrob Agents Chemother. 2006;50(5):1887-1889.
19. Smith AJ, Hall V, Thakker B, Gemmell CG. Antimicrobial susceptibility testing of Actinomyces species with 12 antimicrobial agents. J Antimicrob Chemother. 2005;56(2):407-409.
20. Brown-Elliott BA, Crist CJ, Mann LB, Wilson RW, Wallace RJ Jr. In vitro activity of linezolid against slowly growing nontuberculous Mycobacteria. Antimicrob Agents Chemother. 2003;47(5): 1736-1738.
21. Yang SC, Hsueh PR, Lai HC, et al. High prevalence of antimicrobial resistance in rapidly growing mycobacteria in Taiwan. Antimicrob Agents Chemother. 2003;47(6):1958-1962.
22. Shinabarger D. Mechanism of action of the oxazolidinone antibacterial agents. Expert Opin Investig Drugs. 1999;8(8):1195-1202.
23. Colca JR, McDonald WG, Waldon DJ, et al. Crosslinking in the living cell locates the site of action of oxazolidinone antibiotics. J Biol Chem. 2003;278(24):21972-21979.
24. Leach KL, Swaney SM, Colca JR, et al. The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. Mol Cell. 2007;26(3):393-402.
25. Jones RN, Kohno S, Ono Y, Ross JE, Yanagihara K. ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countries. Diagn Microbiol Infect Dis. 2009;64(2):191-201.
26. Farrell DJ, Mendes RE, Ross JE, Jones RN. Linezolid surveillance program results for 2008 (LEADER Program for 2008). Diagn Microbiol Infect Dis. 2009;65(4):392-403.
27. Ross JE, Farrell DJ, Mendes RE, Sader HS, Jones RN. Eight-year (2002-2009) summary of the linezolid (Zyvox® Annual Appraisal of Potency and Spectrum; ZAAPS) program in European countries. J Chemother. 2011;23(2):71-76.
28. Zurenko G, Todd WM, Hafkin BA. Development of linezolid-resistant Enterococcus faecium in two compassionate use program patients treated with linezolid (abstract). Proceedings of the 39th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); San Francisco, CA. September 26-29, 1999.
29. Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, DenBesten K, Quinn J P. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet. 2001;357(9263):1179.
30. Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet. 2001;358(9277):207-208.
31. Potoski BA, Adams J, Clarke L, et al. Epidemiological profile of linezolid-resistant coagulase-negative staphylococci. Clin Infect Dis. 2006;43(2):165-171.
32. Jones RN, Fritsche TR, Sader HS, Ross JE. Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries. Diagn Microbiol Infect Dis. 2007;59(2):199-209.
33. Mutnick AH, Enne V, Jones RN. Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program. Ann Pharmacother. 2003;37(6):769-774.
34. Meka VG, Gold HS. Antimicrobial resistance to linezolid. Clin Infect Dis. 2004;39(7):1010-1015.
35. Kelly S, Collins J, Maguire M, et al. An outbreak of colonization with linezolid-resistant Staphylococcus epidermidis in an intensive therapy unit. J Antimicrob Chemother. 2008;61(4):901-907.
36. Prystowsky J, Siddiqui F, Chosay J, et al. Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob Agents Chemother. 2001;45(7):2154-2156.
37. Farrell DJ, Mendes RE, Ross JE, Sader HS, Jones RN. LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States. Antimicrob Agents Chemother. 2011;55(8):3684-3690.
38. Kola A, Kirschner P, Gohrbandt B, et al. An infection with linezolid-resistant S. aureus in a patient with left ventricular assist system. Scand J Infect Dis. 2007;39(5):463-465.
39. Dobbs TE, Patel M, Waites KB, Moser SA, Stamm AM, Hoesley CJ. Nosocomial spread of Enterococcus faecium resistant to vancomycin and linezolid in a tertiary care medical center. J Clin Microbiol. 2006;44(9):3368-3370.
40. Miller K, O'Neill AJ, Wilcox MH, Ingham E, Chopra I. Delayed development of linezolid resistance in Staphylococcus aureus following exposure to low levels of antimicrobial agents. Antimicrob Agents Chemother. 2008;52(6):1940-1944.
41. Kehrenberg C, Schwarz S, Jacobsen L, Hansen LH, Vester B. A new mechanism for chloramphenicol, forfenicol and clindamycin resistance: methylation of 23S ribosomal RNA at A2503. Mol Microbiol. 2005;57(4):1064-1073.
42. Toh SM, Xiong L, Arias CA, et al. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol Microbiol. 2007;64(6):1506-1514.
43. Welshman IR, Sisson TA, Jungbluth GL, Stalker DJ, Hopkins NK. Linezolid absolute bioavailability and the effect of food on oral bio-availability. Biopharm Drug Dispos. 2001;22(3):91-97.
44. Gee T, Ellis R, Marshall G, Andrews J, Ashby J, Wise R. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother. 2001;45(6):1843-1846.
45. Slatter JG, Stalker DJ, Feenstra KL, et al. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C] linezolid to healthy human subjects. Drug Metab Dispos. 2001;29(8):1136-1145.
46. Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet. 2003; 42(13):1129-1140.
47. Grunder G, Zysset-Aschmann Y, Vollenweider F, Maier T, Krähenbühl S, Drewe J. Lack of pharmacokinetic interaction between linezolid and antacid in healthy volunteers. Antimicrob Agents Chemother. 2006;50(1):68-72.
48. Keel RA, Schaeftlein A, Kloft C, et al. Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis. Antimicrob Agents Chemother. 2011;55(7):3393-3398.
49. Stalker DJ, Jungbluth GL, Hopkins NK, Batts DH. Pharmacokinetics and tolerance of single-and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic in healthy volunteers. J Antimicrob Chemother. 2003;51(5):1239-1246.
50. MacGowan A P. Pharmacokinetic and pharmacodynamic profle of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother. 2003;51 Suppl 2:ii 17-25.
51. Meagher AK, Forrest A, Rayner CR, Birmingham MC, Schentag JJ. Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrob Agents Chemother. 2003;47(2):548-553.
52. Adembri C, Fallani S, Cassetta MI, et al. Linezolid pharmacoki- netic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. Int J Antimicrob Agents. 2008;31(2):122-129.
53. Sisson TL, Jungbluth GL, Hopkins NK. Age and sex effects on the pharmacokinetics of linezolid. Eur J Clin Pharmacol. 2002;57(11):793-797.
54. Clemett D, Markham A. Linezolid. Drugs. 2000;59(4):815-827.
55. Dehghanyar P, Bürger C, Zeitlinger M, et al. Penetration of linezolid into soft tissues of healthy volunteers after single and multiple doses. Antimicrob Agents Chemother. 2005;49(6):2367-2371.
56. Lovering AM, Zhang J, Bannister GC, et al. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob Chemother. 2002;50:73-77.
57. Kutscha-Lissberg F, Hebler U, Muhr G, Köller M. Linezolid penetration into bone and joint tissues infected with methicillin- resistant staphylococci. Antimicrob Agents Chemother. 2003;47(12): 3964-3966.
58. Boselli E, Breilh D, Rimmelé T, et al. Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit Care Med. 2005;33(7):1529-1533.
59. Honeybourne D, Tobin C, Jevons G, Andrews J, Wise R. Intrapulmonary penetration of linezolid. Antimicrob Chemother. 2003;51(6): 1431-1434.
60. Conte JE Jr, Golden JA, Kipps J, Zurlinden E. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother. 2002;46(5):1475-1480.
61. Tsona A, Metallidis S, Foroglou N, et al. Linezolid penetration into cere-brospinal fluid and brain tissue. J Chemother. 2010;22(1): 17-19.
62. Boak LM, Li J, Spelman D, du Cros P, Nation RL, Rayner CR. Successful treatment and cerebrospinal fluid penetration of oral linezolid in a patient with coagulase-negative Staphylococcus ventriculitis. Ann Pharmacother. 2006;40(7-8):1451-1455.
63. Myrianthefs P, Markantonis SL, Vlachos K, et al. Serum and Cere-brospinal Fluid Concentrations of Linezolid in Neurosurgical Patients. Antimicrob Agents Chemother. 2006;50(12):3971-3976.
64. Beer R, Engelhardt K W, Pfausler B, et al. Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains. Antimicrob Agents Chemother. 2007;51:379-382.
65. Viaggi B, Paolo AD, Danesi R, et al. Linezolid in the central nervous system: comparison between cerebrospinal fluid and plasma pharma-cokinetics. Scand J Infect Dis. 2011;43(9):721-727.
66. Prydal JI, Jenkins DR, Lovering A, Watts A. The pharmacokinetics of linezolid in the non-infamed human eye. Br J Ophthalmol. 2005;89(11):1418-1419.
67. Vázquez EG, Mensa J, López Y, et al. Penetration of linezolid into the anterior chamber (aqueous humor) of the human eye after intravenous administration. Antimicrob Agents Chemother. 2004;48(2): 670-672.
68. Buerger C, Plock N, Dehghanyar P, Joukhadar C, Kloft C. Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis. Antimicrob Agents Chemother. 2006;50(7):2455-2463.
69. Rao GG, Steger A, Tobin CM. linezolid levels in pancreatic secretions. J Antimicrob Chemother. 2001; 48(6):931-932.
70. DePestel DD, Peloquin CA, Carver PL. Peritoneal dialysis fluid concentrations of linezolid in the treatment of vancomycin-resistant Enterococcus faecium peritonitis. Pharmacotherapy. 2003;23(10):1322-1326.
71. Dehghanyar P, Bürger C, Zeitlinger M, et al. Penetration of linezolid into soft tissues of healthy volunteers after single and multiple doses. Antimicrob Agents Chemother. 2005;49(6):2367-2371.
72. Sagirli O, Onal A, Toker S, Oztunç A. Determination of linezolid in human breast milk by high-performance liquid chromatography with ultraviolet detection. J AOAC Int. 2009;92(6):1658-1662.
73. Wilcox MH, Kite P, Mills K, Sugden S. In situ measurement of linezolid and vancomycin concentrations in intravascular catheter-associated biofilm. J Antimicrob Chemother. 2001;47(2):171-175.
74. Wiederhold N P, Coyle EA, Raad II, Prince RA, Lewis RE. Antibacterial activity of linezolid and vancomycin in an in vitro pharmacodynamic model of Gram-positive catheter-related bacteraemia. J Antimicrob Chemother. 2005;55(5):792-795.
75. Bayston R, Nuradeen B, Ashraf W, Freeman BJ. Antibiotics for the eradication of Propionibacterium acnes biofilms in surgical infection. J Antimicrob Chemother. 2007;60(6):1298-1301.
76. Leite B, Gomes F, Teixeira P, Souza C, Pizzolitto E, Oliveira R. In vitro activity of daptomycin, linezolid and rifampicin on Staphylococcus epidermidis bioflms. Curr Microbiol. 2011;63(3):313-317.
77. Bayston R, Ullas G, Ashraf W. The action of linezolid or vancomycin on bioflms in ventriculoperitoneal shunts in vitro. Antimicrob Agents Chemother. 2012. [Epub ahead of print.]
78. Holmberg A, Mörgelin M, Rasmussen M. Effectiveness of ciprofoxacin or linezolid in combination with rifampicin against Enterococcus faecalis in bioflms. J Antimicrob Chemother. 2012;67(2):433-439.
79. Sandoe JA, Wysome J, West A P, Heritage J, Wilcox MH. Measurement of ampicillin, vancomycin, linezolid and gentamicin activity against enterococcal biofilms. J Antimicrob Chemother. 2006;57(4): 767-770.
80. Brier ME, Stalker DJ, Aronoff GR, et al. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother. 2003;47(9):2775-2780.
81. Hendershot PE, Jungbluth GL, Cammarata SK, Hopkins NJ. Pharmacokinetics of linezolid in patients with liver disease. J Antimicrob Chemother. 1999;44(Suppl A):55.
82. Fiaccadori E, Maggiore U, Rotelli C, et al. Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofltration in patients with acute renal failure. Crit Care Med. 2004;32(12):2437-2442.
83. Meyer B, Kornek G V, Nikfardjam M, et al. Multiple-dose pharmacokinetics of linezolid during continuous venovenous haemofiltration. J Antimicrob Chemother. 2005;56(1):172-179.
84. Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis. 2005;41(8):1159-1166.
85. Kearns GL, Abdel-Rahman SM, Blumer JL, et al. Single dose pharmacokinetics of linezolid in infants and children. Pediatr Infect Dis J. 2000;19(12):1178-1184.
86. Wise R, Andrews JM, Boswell FJ, Ashby J P. The in-vitro activity of linezolid (U-100766) and tentative breakpoints. J Antimicrob Chemother. 1998;42(6):721-728.
87. Bowker KE, Wootton M, Holt HA, MacGowan A P. In vitro activity of linezolid against Gram-positive isolates causing infection in continuous ambulatory peritoneal dialysis patients. J Antimicrob Chemother. 2002;49(3):578-580.
88. Zurenko GE, Yagi BH, Schaadt RD, et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother. 1996;40(4):839-845.
89. Rybak MJ, Cappelletty DM, Moldovan T, Aeschlimann JR, Kaatz G W. Comparative in vitro activities and postantibiotic effects of the oxazolidi-none compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium. Anti- microb Agents Chemother. 1998;42(3): 721-724.
90. Wilcox M, Nathwani D, Dryden M. Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections. J Antimicrob Chemother. 2004;53(2):335-344.
91. Wilcox MH, Tack KJ, Bouza E, et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis. 2009; 48(2):203-212.
92. Falagas ME, Siempos II, Vardakas KZ. Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis. 2008;8(1):53-66.
93. Beibei L, Yun C, Mengli C, Nan B, Xuhong Y, Rui W. Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials. Int J Antimicrob Agents. 2010;35(1):3-12.
94. Jang HC, Kim SH, Kim KH, et al. Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem. Clin Infect Dis. 2009;49(3): 395-401.
95. Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis. 2005;41(10):1407-1415.
96. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C; Linezolid CSSTI Study Group. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2005;49(6):2260-2266.
97. Stevens DL, Smith LG, Bruss JB, et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2000;44(12):3408-3413.
98. Bounthavong M, Hsu DI. Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis. Curr Med Res Opin. 2010;26(2):407-421.
99. Saroglou M, Tryfon S, Ismailos G, et al. Pharmacokinetics of Linezolid and Ertapenem in experimental parapneumonic pleural effusion. J Infamm (Lond). 2010;7:22.
100. San Pedro GS, Cammarata SK, Oliphant TH, Todisco T; Linezolid Community-Acquired Pneumonia Study Group. Linezolid versus ceftriaxone/cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumonia. Scand J Infect Dis. 2002;34(10):720-728.
101. Walkey AJ, O'Donnell MR, Wiener RS. Linezolid versus glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials. Chest. 2011;139(5):1148-1155.
102. Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis. 2012;54(5): 621-629.
103. Rana B, Butcher I, Grigoris P, Murnaghan C, Seaton RA, Tobin CM. Linezolid penetration into osteo-articular tissues. J Antimicrob Chemother. 2002;50(5):747-750.
104. Howden B P, Ward PB, Charles PG, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis. 2004;38(4):521-528.
105. Aneziokoro CO, Cannon J P, Pachucki CT, Lentino JR. The effectiveness and safety of oral linezolid for the primary and secondary treatment of osteomyelitis. J Chemother. 2005;17(6):643-650.
106. Rayner CR, Baddour LM, Birmingham MC, Norden C, Meagher AK, Schentag JJ. Linezolid in the treatment of osteomyelitis: results of compassionate use experience. Infection. 2004;32(1):8-14.
107. Dailey CF, Dileto-Fang CL, Buchanan LV, et al. Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2001;45(8):2304-2308.
108. Patel R, Rouse MS, Piper KE, Steckelberg JM. Linezolid therapy of vancomycin-resistant Enterococcus faecium experimental endocarditis. Antimicrob Agents Chemother. 2001;45(2):621-623.
109. Muñoz P, Rodríguez-Creixéms M, Moreno M, Marín M, Ramallo V, Bouza E; GAME Study Group. Linezolid therapy for infective endocarditis. Clin Microbiol Infect. 2007;13(2):211-215.
110. Tsigrelis C, Singh K V, Coutinho TD, Murray BE, Baddour LM. Vancomycin-resistant Enterococcus faecalis endocarditis: linezolid failure and strain characterization of virulence factors. J Clin Microbiol. 2007;45(2):631-635.
111. Corne P, Marchandin H, Macia JC, Jonquet O. Treatment failure of methicillin-resistant Staphylococcus aureus endocarditis with linezolid. Scand J Infect Dis. 2005;37(11-12):946-949.
112. Falagas ME, Manta KG, Ntziora F, Vardakas KZ. Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother. 2006;58(2): 273-280.
113. Jacqueline C, Asseray N, Batard E, et al. In vivo efficacy of linezolid in combination with gentamicin for the treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents. 2004;24(4):393-396.
114. Nagashima G, Okamoto N, Okuda M, et al. Effect of linezolid against post- neurosurgical meningitis caused by methicillin-resistant Staphylococcus epidermidis: case report. J Infect Chemother. 2008;14(2):147-150.
115. Krueger WA, Kottler B, Will BE, Heininger A, Guggenberger H, Unertl KE. Treatment of meningitis due to methicillin-resistant Staphylococcus epidermidis with linezolid. J Clin Microbiol. 2004;42(2):929-932.
116. Castro P, Soriano A, Escrich C, Villalba G, Sarasa M, Mensa J. Linezolid treatment of ventriculoperitoneal shunt infection without implant removal. Eur J Clin Microbiol Infect Dis. 2005;24(9):603-606.
117. Tsuji Y, Hiraki Y, Matsumoto K, et al. Pharmacokinetics and protein binding of linezolid in cerebrospinal fluid and serum in a case of post-neurosurgical bacterial meningitis. Scand J Infect Dis. 2011;43(11-12):982-985.
118. Zeana C, Kubin CJ, Della-Latta P, Hammer SM. Vancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid: case report and review of the literature. Clin Infect Dis. 2001;33(4):477-482.
119. Faella F, Pagliano P, Fusco U, Attanasio V, Conte M. Combined treatment with ceftriaxone and linezolid of pneumococcal meningitis: a case series including penicillin-resistant strains. Clin Microbiol Infect. 2006;12(4):391-394.
120. Ramírez P, Sahuquillo JM, Cortés C, Kot P, Bonastre JM. Linezolid as rescue therapy for pneumococcal meningitis. Intensive Care Med. 2007;33(5):924-925.
121. Leiti O, Gross J W, Tuazon CU. Treatment of brain abscess caused by Listeria monocytogenes in a patient with allergy to penicillin and trimethoprim-sulfamethoxazole. Clin Infect Dis. 2005; 40(6):907-908.
122. Viganò SM, Edefonti A, Ferraresso M, et al. Successful medical treatment of multiple brain abscesses due to Nocardia farcinica in a paediatric renal transplant recipient. Pediatr Nephrol. 2005;20(8): 1186-1188.
123. Jaksic B, Martinelli G, Perez-Oteyza J, Hartman CS, Leonard LB, Tack KJ. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis. 2006;42(5):597-607.
124. Nannini EC, Keating M, Binstock P, Samonis G, Kontoyiannis D P. Successful treatment of refractory disseminated Mycobacterium avium complex infection with the addition of linezolid and mefoquine. J Infect. 2002;44(3):201-203.
125. Kyle SD, Porter WM. Mycobacterium chelonae infection successfully treated with oral clarithromycin and linezolid. Br J Dermatol. 2004; 151(5):1101.
126. Ntziora F, Falagas ME. Linezolid for the treatment of patients with mycobacterial infections a systematic review. Int J Tuberc Lung Dis. 2007;11(6):606-611.
127. Rubinstein E, Cammarata S, Oliphant T, Wunderink R; Linezolid Nosocomial Pneumonia Study Group. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis. 2001;32(3):402-412.
128. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 2002;34(11): 1481-1490.
129. Rubinstein E, Isturiz R, Standiford HC, et al. Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob Agents Chemother. 2003;47(6):1824-1831.
130. Kaplan SL, Deville JG, Yogev R, et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatr Infect Dis J. 2003;22(8):677-686.
131. Falagas ME, Vardakas KZ. Benefit-risk assessment of linezolid for serious gram-positive bacterial infections. Drug Saf. 2008;31(9): 753-768.
132. Cawley MJ, Lipka O. Intravenous linezolid administered orally: a novel desensitization strategy. Pharmacotherapy. 2006;26(4):563-568.
133. Bishop E, Melvani S, Howden B P, Charles PG, Grayson ML. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicrob Agents Chemother. 2006; 50(4):1599-1602.
134. Kelley W, Resh B, Goldenberg G., Linezolid-induced purpuric medication reaction. J Cutan Pathol. 2009;36(7):793-795.
135. Esposito L, Kamar N, Guilbeau-Frugier C, Mehrenberger M, Modesto A, Rostaing L. Linezolid-induced interstitial nephritis in a kidney-transplant patient. Clin Nephrol. 2007;68(5):327-329.
136. Savard S, Desmeules S, Riopel J, Agharazii M. Linezolid-associated acute interstitial nephritis and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome. Am J Kidney Dis. 2009; 54(6):e17-e20.
137. Apodaca AA, Rakita RM. Linezolid-induced lactic acidosis. N Engl J Med. 2003;348:86-87.
138. Su E, Crowley K, Carcillo JA, Michaels MG. Linezolid and lactic acidosis: a role for lactate monitoring with long-term linezolid use in children. Pediatr Infect Dis J. 2011;30(9):804-806.
139. Scotton P, Fuser R, Torresan S, et al. Early linezolid-associated lactic acidosis in a patient treated for tuberculous spondylodiscitis. Infection. 2008;36(4):387-388.
140. Contou D, Fichet J, Grimaldi D, Cariou A. Early life-threatening lactic acidosis following a single infusion of linezolid. Int J Antimicrob Agents. 2011;38(1):84-85.
141. Palenzuela L, Hahn NM, Nelson RP Jr, et al. Does linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis? Clin Infect Dis. 2005;40(12):e113-e116.
142. Garrabou G, Soriano A, López S, et al. Reversible inhibition of mitochondrial protein synthesis during linezolid-related hyperlactatemia. Antimicrob Agents Chemother. 2007;51(3):962-967.
143. Carson J, Cerda J, Chae JH, Hirano M, Maggiore P. Severe lactic acidosis associated with linezolid use in a patient with the mitochondrial DNA A2706G polymorphism. Pharmacotherapy. 2007; 27(5): 771-774.
144. French G. Safety and tolerability of linezolid. J Antimicrob Chemother. 2003;51 Suppl 2:ii 45-53.
145. Monson T, Schichman SA, Zent CS. Linezolid-induced pure red blood cell aplasia. Clin Infect Dis. 2002;35(3):E29-E31.
146. Attassi K, Hershberger E, Alam R, Zervos MJ. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis. 2002;34(5): 695-698.
147. Gerson SL, Kaplan SL, Bruss JB. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother. 2002;46(8):2723-2726.
148. Nasraway SA, Shorr A F, Kuter DJ, O'Grady N, Le VH, Cammarata SK. Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use. Clin Infect Dis. 2003;37(12):1609-1616.
149. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C; Linezolid CSSTI Study Group. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2005;49(6):2260-2266.
150. Bernstein WB, Trotta RF, Rector JT, Tjaden JA, Barile AJ. Mechanisms for linezolid-induced anemia and thrombocytopenia. Ann Pharmacother. 2003;37(4):517-520.
151. Orrick JJ, Johns T, Janelle J, Ramphal R. Thrombocytopenia secondary to linezolid administration: what is the risk? Clin Infect Dis. 2002;35(3):348-349.
152. Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis. 2003;36(2):159-168.
153. Kuter DJ, Tillotson GS. Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid. Pharmacotherapy. 2001;8:1010-1013.
154. Lin YH, Wu VC, Tsai IJ. High frequency of linezolid-associated throm- bocytopenia among patients with renal insuffciency. Int J Antimicrob Agents. 2006;28(4):345-351.
155. Hiraki Y, Tsuji Y, Matsumoto K, Morita K, Kamimura H, Karube Y. Influence of linezolid clearance on the induction of thrombocytopenia and reduction of hemoglobin. Am J Med Sci. 2011;342(6):456-460.
156. Tsuji Y, Hiraki Y, Matsumoto K, et al. Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction. J Infect Chemother. 2011;17(1):70-75.
157. Cohen N, Mihu CN, Seo SK, et al. Hematologic safety profile of linezolid in the early periengraftment period after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15(10): 1337-1341.
158. De Bus L, Depuydt P, Libbrecht L, et al. Severe drug-induced liver injury associated with prolonged use of linezolid. J Med Toxicol. 2010;6(3):322-326.
159. Bressler AM, Zimmer SM, Gilmore JL, Somani J. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis. 2004;4(8):528-531.
160. Legout L, Senneville E, Gomel JJ, Yazdanpanah Y, Mouton Y. Linezolid-induced neuropathy. Clin Infect Dis. 2004;38(5): 767-768.
161. Rucker JC, Hamilton SR, Bardenstein D, Isada CM, Lee MS. Linezolid-associated toxic optic neuropathy. Neurology. 2006;66(4): 595-598.
162. Javaheri M, Khurana RN, O'hearn TM, Lai MM, Sadun AA. Linezolid- induced optic neuropathy: a mitochondrial disorder? Br J Ophthalmol. 2007;91(1):111-115.
163. Joshi L, Taylor SR, Large O, Yacoub S, Lightman S. A case of optic neuropathy after short-term linezolid use in a patient with acute lymphocytic leukemia. Clin Infect Dis. 2009;48(7):e73-e74.
164. Thai XC, Bruno-Murtha LA. Bell's palsy associated with linezolid therapy: case report and review of neuropathic adverse events. Pharmacotherapy. 2006;26(8):1183-1189.
165. Wynalda MA, Hauer MJ, Wienkers LC. Oxidation of the novel oxazolidinone antibiotic linezolid in human liver microsomes. Drug Metab Dispos. 2000;28(9):1014-1017.
166. Hendershot PE, Antal EJ, Welshman IR, Batts DH, Hopkins NK. Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr. J Clin Pharmacol. 2001;41(5): 563-572.
167. Wigen CL, Goetz MB. Serotonin syndrome and linezolid. Clin Infect Dis. 2002;34(12):1651-1652.
168. Bergeron L, Boulé M, Perreault S. Serotonin toxicity associated with concomitant use of linezolid. Ann Pharmacother. 2005;39(5): 956-961.
169. Huang V, Gortney JS. Risk of serotonin syndrome with concomitant administration of linezolid and serotonin agonists. Pharmacotherapy. 2006;26(12):1784-1793.
170. Butterfeld JM, Lawrence KR, Reisman A, Huang DB, Thompson CA, Lodise T P. Comparison of serotonin toxicity with concomitant use of either linezolid or comparators and serotonergic agents: an analysis of Phase III and IV randomized clinical trial data. J Antimicrob Chemother. 2012;67(2):494-502.
171. Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis. 2006;42(11):1578-1583.
172. Bounthavong M, Zargarzadeh A, Hsu DI, Vanness DJ. Cost-effectiveness analysis of linezolid, daptomycin, and vancomycin in methicillin- resistant Staphylococcus aureus: complicated skin and skin structure infection using Bayesian methods for evidence synthesis. Value Health. 2011;14(5):631-639.
173. Schürmann D, Sorensen S V, De Cock E, Duttagupta S, Resch A. Cost- effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in Germany. Eur J Health Econ. 2009;10(1):65-79.
174. De Cock E, Krueger WA, Sorensen S, et al. Cost-effectiveness of linezolid vs vancomycin in suspected methicillin-resistant Staphy- lococcus aureus nosocomial pneumonia in Germany. Infection. 2009;37(2):123-132.
175. Patanwala AE, Erstad BL, Nix DE. Cost-effectiveness of linezolid and vancomycin in the treatment of surgical site infections. Curr Med Res Opin. 2007;23(1):185-193.